OPENTOX

OpenTox - An Open Source Predictive Toxicology Framework

 Coordinatore DOUGLAS CONNECT 

 Organization address address: Baermeggenweg 14
city: ZEININGEN
postcode: 4314

contact info
Titolo: Ms.
Nome: Nicki
Cognome: Douglas
Email: send email
Telefono: -1332
Fax: -4782

 Nazionalità Coordinatore Switzerland [CH]
 Totale costo 3˙775˙680 €
 EC contributo 2˙975˙360 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2007-A
 Funding Scheme CP-FP
 Anno di inizio 2008
 Periodo (anno-mese-giorno) 2008-09-01   -   2011-08-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    DOUGLAS CONNECT

 Organization address address: Baermeggenweg 14
city: ZEININGEN
postcode: 4314

contact info
Titolo: Ms.
Nome: Nicki
Cognome: Douglas
Email: send email
Telefono: -1332
Fax: -4782

CH (ZEININGEN) coordinator 0.00
2    ALBERT-LUDWIGS-UNIVERSITAET FREIBURG

 Organization address address: FAHNENBERGPLATZ
city: FREIBURG
postcode: 79085

contact info
Titolo: Dr.
Nome: Andreas
Cognome: Karwath
Email: send email
Telefono: -8944
Fax: -8922

DE (FREIBURG) participant 0.00
3    DAVID ANTHONY GALLAGHER

 Organization address address: "Park Mews, Park Road 3"
city: CONGRESBURY
postcode: BS49 5HR

contact info
Titolo: Dr.
Nome: David
Cognome: Gallagher
Email: send email
Telefono: -446117
Fax: -

UK (CONGRESBURY) participant 0.00
4    FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V

 Organization address address: Hansastrasse 27C
city: MUENCHEN
postcode: 80686

contact info
Titolo: Ms.
Nome: Andrea
Cognome: Zeumann
Email: send email
Telefono: -3968
Fax: -8779

DE (MUENCHEN) participant 0.00
5    HELMA CHRISTOPH

 Organization address address: TALSTRASSE 20
city: FREIBURG
postcode: 79102

contact info
Titolo: Dr.
Nome: Christoph
Cognome: Helma
Email: send email
Telefono: -7592050
Fax: -

DE (FREIBURG) participant 0.00
6    IDEACONSULT LIMITED LIABILITY COMPANY

 Organization address address: ANGEL KANCHEV 4
city: SOFIA
postcode: 1000

contact info
Titolo: Mr.
Nome: Vedrin
Cognome: Jeliazkov
Email: send email
Telefono: +359 887818654
Fax: +359 2 9526265

BG (SOFIA) participant 0.00
7    INSTITUTE OF BIOMEDICAL CHEMISTRY - RUSSIAN ACADEMY OF SCIENCES

 Organization address address: POGODINSKAYA STREET 10
city: MOSKVA
postcode: 119121

contact info
Titolo: Prof.
Nome: Poroikov
Cognome: Vladimir
Email: send email
Telefono: +007 495 245-27-53
Fax: +007 495 245-08-57

RU (MOSKVA) participant 0.00
8    ISTITUTO SUPERIORE DI SANITA

 Organization address address: Viale Regina Elena 299
city: ROMA
postcode: 161

contact info
Titolo: Ms.
Nome: Rosa Maria
Cognome: Martoccia
Email: send email
Telefono: -49902655
Fax: -3473

IT (ROMA) participant 0.00
9    NATIONAL TECHNICAL UNIVERSITY OF ATHENS - NTUA

 Organization address address: HEROON POLYTECHNIOU 9 ZOGRAPHOU CAMPUS
city: ATHINA
postcode: 15780

contact info
Titolo: Prof.
Nome: Yannis
Cognome: Polyzos
Email: send email
Telefono: -7722230
Fax: -7722140

EL (ATHINA) participant 0.00
10    SEASCAPE LEARNING CO PRIVATE LTD

 Organization address address: "DOUBLE STOREY, NEW RAJINDER NGR 271"
city: NEW DELHI
postcode: 110060

contact info
Titolo: Mr.
Nome: Sunil
Cognome: Chawla
Email: send email
Telefono: 91-9810305923
Fax: 91 20 2569 0087

IN (NEW DELHI) participant 0.00
11    TECHNISCHE UNIVERSITAET MUENCHEN

 Organization address address: Arcisstrasse 21
city: MUENCHEN
postcode: 80333

contact info
Titolo: Ms.
Nome: Ulrike
Cognome: Ronchetti
Email: send email
Telefono: +49 89 289 22 616
Fax: +49 89 289 22 620

DE (MUENCHEN) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

integration    toxicity    confidential    developers    algorithms    opentox    endpoints    models    sar       validation    data    attract    toxicological    framework   

 Obiettivo del progetto (Objective)

'The goal of the OpenTox project is to develop a predictive toxicology framework with a unified access to toxicological data, (Q)SAR models and supporting information. It will provide tools for the integration of data from various sources (public and confidential), for the generation and validation of (Q)SAR models, libraries for the development and integration of new (Q)SAR algorithms, and validation routines. OpenTox will attract toxicological experts without (Q)SAR expertise as well as model and algorithm developers. It will move beyond existing attempts to solve individual research issues, by providing a flexible and user friendly framework that integrates existing solutions and new developments. OpenTox will be relevant for REACH as it gives risk assessors simple access to experimental data, (Q)SAR models and toxicological information that adheres to European and international regulatory requirements. OpenTox will be published as an open source project to allow a critical evaluation of its algorithms, to promote dissemination, and to attract external developers. Facilities for the inclusion of confidential in-house data and for accessing commercial prediction systems will be included. OpenTox will contain high-quality data and (Q)SAR models for chronic, genotoxic and carcinogenic effects. These are the endpoints with the greatest potential to reduce animal testing. The impact of OpenTox will however go beyond REACH and long-term effects, because it will be straightforward to create models for other endpoints (e.g,. sensitisation, liver-toxicity, cardio-toxicity, ecotoxicity). The proposed framework will support the development of new (Q)SAR models and algorithms by automating routine tasks, providing a testing and validation environment and allowing the easy addition of new data. For this reason we expect, that OpenTox will lead to (Q)SAR models for further toxic endpoints and generally improve the acceptance and reliability of (Q)SAR models.'

Altri progetti dello stesso programma (FP7-HEALTH)

KALADRUG-R (2008)

New tools for monitoring drug resistance and treatment response in visceral leishmaniasis in the Indian subcontinent

Read More  

FOCUS (2010)

Fixed Dose Combination drugs for Secondary Cardiovascular Prevention

Read More  

DEVELOPAKURE (2012)

Clinical Development of Nitisinone for Alkaptonuria

Read More